February 15, 2024
The Biden administration has asked an Ohio federal judge to dismiss a lawsuit challenging the Medicare price negotiation program, contending that the local business group serving as lead plaintiff lacks standing to sue.
December 18, 2023
Local business groups still haven't explained why they have a stake in Medicare's effort to negotiate lower prices with drugmakers, the U.S. Department of Health and Human Services said in a federal filing in Ohio Friday.
October 06, 2023
Lawsuits from Big Pharma and big business challenging Medicare's new power to negotiate drug prices are hurtling toward pivotal tests of lofty legal theories and the Biden administration's creative efforts to save its signature health care accomplishment. Here, Law360 explores the litigation landscape in a detailed map that will be updated as the saga evolves.
September 29, 2023
An Ohio federal judge on Friday rejected a request from the U.S. Chamber of Commerce and three business groups for a temporary block on Medicare drug price negotiations.
September 15, 2023
The U.S. Chamber of Commerce and a trio of state business groups urged an Ohio federal judge Friday to temporarily block the new Medicare drug price negotiation program, arguing that the Inflation Reduction Act provision is a price-setting scheme dressed "in the garb of negotiations."
September 01, 2023
Novartis Pharmaceuticals Corp. on Friday joined the growing list of pharmaceutical companies challenging the Inflation Reduction Act, filing suit in New Jersey federal court just days after the Biden administration revealed the list of drugs in the inaugural round of Medicare price negotiations.
August 25, 2023
The AARP urged an Ohio federal judge not to stop the federal government from negotiating the prices of certain prescription drugs paid for under the Medicare program, arguing that an injunction sought by the U.S. Chamber of Commerce would keep prices unsustainably high to the detriment of the AARP's members and the general public.
August 14, 2023
A barrage of legal challenges to landmark legislation empowering Medicare to negotiate drug prices is little more than a failed lobbying campaign "masquerading as constitutional theory," the U.S. Department of Health and Human Services said in its first official rebuttal in the high-stakes litigation.
July 21, 2023
A head-spinning spree of rulings and new lawsuits in 2023's first half is reverberating across the health care industry and auguring a dizzying denouement in the year's final months that may well upend assumptions about drug prices and approvals, the False Claims Act and the powers of federal regulators.
July 11, 2023
Merck & Co. on Tuesday likened the Inflation Reduction Act's new system of drug-price negotiations to an oppressive political regime and derided the Biden administration's rush for legal cover amid a cloudburst of litigation as "highly dubious" and "constitutionally irrelevant."